Protara Therapeutics (TARA) Competitors $2.39 +0.10 (+4.37%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TARA vs. CSBR, LJPC, ADCT, OPT, MDWD, NBTX, CRBU, DMAC, ACTU, and SCPHShould you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Champions Oncology (CSBR), La Jolla Pharmaceutical (LJPC), ADC Therapeutics (ADCT), Opthea (OPT), MediWound (MDWD), Nanobiotix (NBTX), Caribou Biosciences (CRBU), DiaMedica Therapeutics (DMAC), Actuate Therapeutics (ACTU), and scPharmaceuticals (SCPH). These companies are all part of the "medical" sector. Protara Therapeutics vs. Champions Oncology La Jolla Pharmaceutical ADC Therapeutics Opthea MediWound Nanobiotix Caribou Biosciences DiaMedica Therapeutics Actuate Therapeutics scPharmaceuticals Protara Therapeutics (NASDAQ:TARA) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment. Does the MarketBeat Community prefer TARA or CSBR? Champions Oncology received 116 more outperform votes than Protara Therapeutics when rated by MarketBeat users. However, 65.38% of users gave Protara Therapeutics an outperform vote while only 60.24% of users gave Champions Oncology an outperform vote. CompanyUnderperformOutperformProtara TherapeuticsOutperform Votes3465.38% Underperform Votes1834.62% Champions OncologyOutperform Votes15060.24% Underperform Votes9939.76% Do institutionals and insiders hold more shares of TARA or CSBR? 38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 12.5% of Protara Therapeutics shares are held by insiders. Comparatively, 47.0% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is TARA or CSBR more profitable? Protara Therapeutics has a net margin of 0.00% compared to Champions Oncology's net margin of -6.58%. Champions Oncology's return on equity of 0.00% beat Protara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -55.96% -49.06% Champions Oncology -6.58%N/A -12.80% Which has higher earnings and valuation, TARA or CSBR? Champions Oncology has higher revenue and earnings than Protara Therapeutics. Champions Oncology is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$40.42M-$2.82-0.85Champions Oncology$50.15M1.23-$7.28M-$0.26-17.50 Which has more risk and volatility, TARA or CSBR? Protara Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Does the media refer more to TARA or CSBR? In the previous week, Protara Therapeutics had 4 more articles in the media than Champions Oncology. MarketBeat recorded 5 mentions for Protara Therapeutics and 1 mentions for Champions Oncology. Champions Oncology's average media sentiment score of 1.04 beat Protara Therapeutics' score of -0.05 indicating that Champions Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Champions Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TARA or CSBR? Protara Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 904.18%. Champions Oncology has a consensus price target of $6.00, indicating a potential upside of 31.87%. Given Protara Therapeutics' higher probable upside, equities analysts clearly believe Protara Therapeutics is more favorable than Champions Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Champions Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryChampions Oncology beats Protara Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARA vs. The Competition Export to ExcelMetricProtara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.31M$3.03B$5.20B$8.85BDividend YieldN/A1.86%5.53%4.08%P/E Ratio-0.8520.9377.9314.95Price / SalesN/A298.381,246.7687.31Price / CashN/A172.5640.9036.92Price / Book0.604.607.196.55Net Income-$40.42M-$41.63M$119.54M$226.22M7 Day Performance-3.24%2.57%2.12%3.77%1 Month Performance27.13%-2.51%-2.43%4.64%1 Year Performance112.44%28.21%34.52%29.21% Protara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARAProtara Therapeutics1.9761 of 5 stars$2.39+4.4%$24.00+904.2%+117.3%$49.31MN/A-0.8530CSBRChampions Oncology4.1947 of 5 stars$4.30-0.5%$6.00+39.4%-16.0%$58.50M$50.15M0.00143Positive NewsLJPCLa Jolla PharmaceuticalN/AN/AN/AN/A$155.11M$75.72M51.8461ADCTADC Therapeutics2.9029 of 5 stars$1.94-2.0%$8.25+325.3%+182.5%$187.58M$69.56M-0.81310Positive NewsOPTOpthea2.4834 of 5 stars$3.13-4.6%$12.00+283.4%+64.6%$182.79M$120,000.000.008MDWDMediWound1.2081 of 5 stars$16.76-0.1%$29.00+73.0%+89.4%$180.84M$18.69M-7.7580Upcoming EarningsNBTXNanobiotix1.9953 of 5 stars$3.83-5.9%$11.50+200.3%-34.0%$180.51M$39.18M0.00100Positive NewsCRBUCaribou Biosciences2.9088 of 5 stars$1.98+1.0%$11.25+468.2%-64.5%$179.29M$34.48M-1.20100DMACDiaMedica Therapeutics1.8275 of 5 stars$4.19+4.2%$7.00+67.1%+84.3%$179.16MN/A-7.4820High Trading VolumeACTUActuate TherapeuticsN/A$9.00+4.9%N/AN/A$175.77MN/A0.0010Gap UpSCPHscPharmaceuticals3.8327 of 5 stars$3.46+3.0%$15.00+333.5%-39.0%$173.14M$13.59M-1.7830 Related Companies and Tools Related Companies CSBR Alternatives LJPC Alternatives ADCT Alternatives OPT Alternatives MDWD Alternatives NBTX Alternatives CRBU Alternatives DMAC Alternatives ACTU Alternatives SCPH Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TARA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARA Stock Alerts